| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press.
ARTICLE |
Cost-Effectiveness Analysis Based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS)
For the ALTS Group
Affiliations of authors: Department of Obstetrics and Gynecology, Duke University, Durham, NC (SLK, ERM); Department of Health Policy and Management, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA (JJK, SJG); Departments of Oncology and Medicine, Georgetown University Medical Center and Cancer Clinical and Economic Outcomes Core, Lombardi Comprehensive Cancer Center, Washington, DC (WFL, JSM); Division of Cancer Epidemiology and Genetics (MS), Division of Cancer Prevention (DS), National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD
Correspondence to: Shalini L. Kulasingam, PhD, Duke Center for Clinical Health Policy Research, 2200 W. Main St., Ste. 220, Durham, NC 27705 (e-mail: kulas002{at}mc.duke.edu).
Background: The ALTS (atypical squamous cells of undetermined significance [ASCUS] and low-grade squamous intraepithelial lesion [LSIL] Triage Study) suggests that, for women diagnosed with ASCUS, human papillomavirus (HPV) DNA testing followed by referral to colposcopy of only those women with oncogenic HPV (i.e., HPV DNA testing) is as effective at detecting cervical intraepithelial neoplasia (CIN) 3 or cancer (CIN3+) as referring all women with ASCUS for immediate colposcopy. We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations. Methods: Data from the ALTS trial were used in conjunction with medical care costs in a short-term decision model. The model compared the incremental costs per case of CIN3+ detected as measured by the incremental cost-effectiveness ratio (ICER) for the following management strategies for women with ASCUS: immediate colposcopy, HPV DNA testing, and conservative management with up to three cytology examinations. Results: The least costly and least sensitive strategy was conservative management with one repeat cytology examination using a threshold of high-grade squamous intraepithelial lesion (HSIL) for referral to colposcopy. Compared with this strategy, triage to colposcopy based on a positive HPV DNA test result had an ICER of $3517 per case of CIN3+ detected. Immediate colposcopy and conservative management with up to three repeat cytology visits detected fewer cases of CIN3+ and were more costly than HPV DNA testing. Immediate colposcopy became cost-effective at $20 370 compared with HPV DNA testing only if colposcopy and biopsy were assumed to be 100% sensitive. Conclusions: HPV DNA testing is an economically viable strategy for triage of ASCUS cytology. The less than perfect sensitivity of colposcopy and biopsy needs to be accounted for in future clinical guidelines and policy analyses.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Human Papillomavirus Triage of Atypical Squamous Cells of Undetermined Significance: Cost-Effective, But At What Cost?
- Joy Melnikow and Stephen Birch
J Natl Cancer Inst 2006 98: 82-83.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  J. J. Kim, J. Ortendahl, and S. J. Goldie Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States Ann Intern Med, October 20, 2009; 151(8): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wentzensen, P. E. Gravitt, D. Solomon, C. M. Wheeler, and P. E. Castle A Study of Amplicor Human Papillomavirus DNA Detection in the Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1341 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Monsonego, G. Pollini, M. J. Evrard, P. Sednaoui, L. Monfort, D. Quinzat, R. Dachez, and K. Syrjanen Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear Int J STD AIDS, June 1, 2008; 19(6): 385 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Datta, L. A. Koutsky, S. Ratelle, E. R. Unger, J. Shlay, T. McClain, B. Weaver, P. Kerndt, J. Zenilman, M. Hagensee, et al. Human Papillomavirus Infection and Cervical Cytology in Women Screened for Cervical Cancer in the United States, 2003-2005 Ann Intern Med, April 1, 2008; 148(7): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Goldhaber-Fiebert, N. K. Stout, J. A. Salomon, K. M. Kuntz, and S. J. Goldie Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination J Natl Cancer Inst, March 5, 2008; 100(5): 308 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Melnikow and S. Birch Human Papillomavirus Triage of Atypical Squamous Cells of Undetermined Significance: Cost-Effective, But At What Cost? J Natl Cancer Inst, January 18, 2006; 98(2): 82 - 83. [Full Text] [PDF]
|
|